Biomedical Engineering Reference
In-Depth Information
131. Friedrichs GS, Patmore L, Bass A (2005) Non-clinical evaluation of ventricular repolariza-
tion (ICH S7B): results of an interim survey of international pharmaceutical companies.
J Pharmacol Toxicol Methods 52:6-11
132. Anonymous (2005) ICH Harmonised Tripartite Guideline, The Non-clinical Evaluation of
the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human
Pharmaceuticals S7B. Recommended for adoption at step 4 of the ICH process on12 May
2005 by the ICH Steering Committee. ICH;
http://www.ich.org/
133. Shah RR (2005) Drugs, QTc interval prolongation and final ICH E14 guideline: an important
milestone with challenges ahead. Drug Saf 28:1009-1028
134. Aronov AM, Goldman BB (2004) A model for identifying HERG K+ channel blockers.
Bioorg Med Chem 12:2307-2315
135. Doddareddy MR, Klaasse EC, Shagufta et al (2010) Prospective validation of a comprehen-
sive in silico hERG model and its applications to commercial compound and drug databases.
ChemMedChem 5:716-729
136. Fenu LA, Teisman A, De Buck SS et al (2009) Cardio-vascular safety beyond hERG: in
silico modelling of a guinea pig right atrium assay. J Comput Aided Mol Des 23:883-895
137. Su BH, Shen MY, Esposito EX et al (2010) In silico binary classification QSAR models
based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage. J Chem Inf
Model 50:1304-1318
138. Nilsson MF, Danielsson C, Skold AC et al (2010) Improved methodology for identifying the
teratogenic potential in early drug development of hERG channel blocking drugs. Reprod
Toxicol 29:156-163
139. Suter W (2006) Predictive value of in vitro safety studies. Curr Opin Chem Biol 10:362-366
140. Ducroq J, Moha ou Maati H, Guilbot S et al (2009) Dexrazoxane protects the heart from
acute doxorubicin-induced QT prolongation: a key role for I(Ks). Br J Pharmacol 159:
93-101
141. Toyoshima S, Kanno A, Kitayama T et al (2005) QT PRODACT: in vivo QT assay in the
conscious dog for assessing the potential
for QT interval prolongation by human
pharmaceuticals. J Pharmacol Sci 99:459-471
142. Takahara A, Sasaki R, Nakamura M et al (2009) Clobutinol delays ventricular repolarization
in the guinea pig heart: comparison with cardiac effects of HERG K+ channel inhibitor
E-4031. J Cardiovasc Pharmacol 54:552-559
143. Cheng HC, Incardona J (2009) Models of torsades de pointes: effects of FPL64176,
DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts.
J Pharmacol Toxicol Methods 60:174-184
144. Roden DM (2004) Human genomics and its impact on arrhythmias. Trends Cardiovasc Med
14:112-116
145. Lazzerini PE, Capecchi PL, Laghi-Pasini F (2010) Anti-Ro/SSA antibodies and cardiac
arrhythmias in the adult: facts and hypotheses. Scand J Immunol 72:213-222
146. Morganroth J (2007) Evaluation of the effect on cardiac repolarization (QTc interval) of
oncologic drugs. Ernst Schering Res Found Workshop (59):171-184
147. Brembilla-Perrot B, Beurrier D, Terrier de la Chaise A (1994) Criteria of QRS duration in
relationship to the age of myocardial infarction. Herz 19:235-242
148. Lehmann MH, Suzuki F, Fromm BS et al (1994) T wave “humps” as a potential electrocar-
diographic marker of the long QT syndrome. J Am Coll Cardiol 24:746-754
149. Miyazaki H, Tagawa M (2002) Rate-correction technique for QT interval in long-term
telemetry ECG recording in beagle dogs. Exp Anim 51:465-475
150. Holzgrefe HH, Cavero I, Gleason CR (2007) Analysis of the nonclinical telemetered ECG:
impact of logging rate and RR bin width in the dog and cynomolgus monkey. J Pharmacol
Methods 56:34-42
